TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Erector Spinae Plane Block vs. Usual Care for ED Patients With Mechanical Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Patients deemed to have mechanical back pain with a component of paravertebral tenderness or paravertebral spasm reported by the patient or noted on examination by treating physician.~Exclusion Criteria:~* previous recipient of erector spinae plane block~* exam concerning for cauda equina syndrome~* current IV drug use~* organ transplant recipient~* history of or suspected bleeding diathesis~* current use of anticoagulants~* sepsis or soft tissue infection at site of the block within last three months~* pregnancy~* overt malignancy involving skin or underlying soft tissue at the site of block~* allergy to any of the research medications~* inability to participate in telephone follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ESP cohort (Type: EXPERIMENTAL): Randomized to receive the ultrasound-guided ESP block.
- Usual care cohort (Type: ACTIVE_COMPARATOR): Randomized to usual care as dictated by the treating emergency physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Participants with a clinical diagnosis of WHIM syndrome must meet all of the following criteria to be eligible for study participation:~1. Be at least 18 years of age.~2. Has signed the current approved informed consent form.~3. Has a genotype-confirmed mutation of chemokine receptor type 4 (CXCR4) consistent with WHIM syndrome.~4. Agree to use effective contraception.~5. Be willing and able to comply with this protocol.~6. Has confirmed ANC less than or equal to (≤) 400/µL or ALC ≤650/µL or both.~Exclusion Criteria:~Participants with any of the following will be excluded from participation in the study:~1. Has known systemic hypersensitivity to the mavorixafor drug substance or its inactive ingredients.~2. Is pregnant or nursing.~3. Has a known history of a positive serology or viral load for human immunodeficiency virus (HIV) or a known history of acquired immunodeficiency syndrome (AIDS).~4. Has, at Screening, laboratory tests meeting one or more of the following criteria:~   * A positive antibody test for hepatitis C virus (HCV), unless documented to have no detectable viral load on 2 independent samples.~  * A positive test for hepatitis B surface antigen (HBsAg).~5. Has any medical or personal condition that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the participant, or may preclude the participant's successful completion of the clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- X4P-001 (Type: EXPERIMENTAL): Initial Treatment Phase: Participants will initiate treatment with mavorixafor at 50 milligrams (mg) once daily (QD) orally or a higher dose, with potential escalation based on area under the curve for absolute neutrophil count and absolute leukocyte count (AUCANC/ALC) values to a maximum total daily dose of 400 mg. Participants are expected to receive treatment for 24 weeks in the initial Treatment Period or until development of a treatment-limiting toxicity (TLT).~Extension Phase: All participants will receive mavorixafor; the dose will not exceed 400 mg. In the Extension Phase, treatment may continue until mavorixafor becomes available via an alternative mechanism (for example, drug is commercially available, an expanded access program, etc.) or until the study is terminated by the sponsor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1, Open-Label, 10 Day Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females ≥ 18 and ≤ 65 years of age with no clinically significant abnormalities identified by a detailed medical history~* Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at least 2 years, surgically sterile for at least 90 days, abstinent, or agree to use contraception from 1 week prior to Day -1 until 30 days after leaving the study center.~* Male subjects must be surgically sterile, abstinent, or agree to use contraception from Day -1 until 30 days after leaving the study center~* BMI ≥ 18.0 kg/m2 and ≤ 35.0 kg/m2~Exclusion Criteria:~* Hypersensitivity to oxazolidinones or any component in the formulation~* History or current significant ophthalmologic or neurologic condition that would adversely affect the clinical assessments or confound the interpretation of the data (e.g., dense cataracts, macular degeneration, retinitis pigmentosa)~* Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antibody test result~* Known genetic condition related to mitochondrial disease or dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- TR-701 FA (Type: EXPERIMENTAL): TR-701 FA 200 mg oral once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* New Deplin® Start~* Only for patients with depression who have been prescribed brand name Deplin® to help metabolic management of depression.~* Clinically depressed patients who have been prescribed Deplin® in combination with an antidepressant.~* At the start of antidepressant therapy~* As augmentation to antidepressant therapy~Exclusion Criteria:~* Patients who do not meet DSM IV criteria for major depression~* If participant indicates that he or she did not get a prescription for Deplin®, he/she will not be able to complete the survey(s).~* For follow-up surveys, if the participant indicates that he/she has not been taking Deplin®, he/she will not be able to complete the survey(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Deplin® (Type: None): Subjects with depression who have been prescribed Deplin® daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Are at least age 18 at screening (Visit 1)~2. Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP~3. No clinically apparent alternative explanation for thrombocytopenia and anemia~Exclusion Criteria:~1. Had eculizumab therapy within three months prior to screening~2. Have STEC-HUS~3. Have a positive direct Coombs test~4. Have an active systemic bacterial or fungal infection requiring antimicrobial therapy (prophylactic antimicrobial therapy administered as standard of care is allowed)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OMS721 low dose (Type: EXPERIMENTAL): Administration of OMS721 at a low dose
- OMS721 medium dose (Type: EXPERIMENTAL): Administration of OMS721 at a medium dose
- OMS721 high dose (Type: EXPERIMENTAL): Administration of OMS721 at a high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent asthma for at least 1-year~* Must use a daily asthma controller medication for at least 4 weeks prior to randomization, including an inhaled corticosteroid (ICS) with or without a long-acting beta agonist (LABA) or other adjunctive asthma therapy OR be using a leukotriene receptor antagonist (LTRA), xanthine or short acting beta agonist (SABA) as a monotherapy.~* Must be able to discontinue current asthma medication~* Must have a history of at least one asthma exacerbation in previous 4 to 52 weeks~Exclusion Criteria:~* Unstable asthma~* Taking high dose ICS with or without other adjunctive therapy who have an Asthma Control Questionnaire 6 (ACQ6) total score ≥ 1.5~* Taking LTRA, xanthine or SABA monotherapy with an ACQ-6 total score \< 1.5 (controlled)~* Chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), or other significant, non-asthmatic, lung disease~* Clinically significant abnormality, illness or disorder of any body or organ system~* Significant underlying cardiovascular condition which may contraindicate use of a beta-agonist.~* History of smoking greater than 10-pack years~* Had an asthma exacerbation within 4 weeks of the Baseline Visit~* Had more than 4 asthma exacerbations or 2 hospitalizations within 52 weeks of the randomization visit~* Known or suspected hypersensitivity or intolerance to corticosteroids, beta-2 agonists, or any of the (inactive ingredients) excipients present in the medications used in this study~* Require the use of chronic systemic steroids, omalizumab, or other monoclonal or polyclonal antibodies~* Requires the use of beta-blockers~* History of life-threatening asthma, including an asthma episode that required intubation and/or was associated with hypercapnia requiring noninvasive ventilatory support~* Lactating, pregnant, or plans to become pregnant during the course of the trial

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate/Formoterol MDI BID (Type: EXPERIMENTAL): MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
- Mometasone Furoate MDI BID (Type: ACTIVE_COMPARATOR): MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Delivery Devices for Osteomyelitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The retrospective study included patients with chronic post-traumatic or postoperative osteomyelitis and excluded patients suffering from hematogenous osteomyelitis or acute post-traumatic or postoperative osteomyelitis.~Exclusion Criteria:~* Other kinds of osteomyelitis.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- combination therapy group (Type: None): antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
- PMMA group (Type: None): antibiotic-loaded polymethyl methacrylate and Vancomycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting to the ED with a chief complaint of abdominal pain of less than or equal to 7 days duration~* Age 18 to 65 years~* Patient deemed by the ED attending physician to require IV opioid analgesia~Exclusion Criteria:~* Current use of prescription or non-prescription opioids~* Long-term use of opioids, chronic pain syndrome~* Clinician suspicion of opioid dependence/abuse~* Clinical suspicion of intoxication~* Pregnancy or breast-feeding~* History of chronic obstructive pulmonary disease, history of sleep apnea, oxygen saturation \< 97%~* Systolic blood pressure \< 100 mm Hg~* Use of monoamine oxidase inhibitors, phenothiazines, or tricyclic antidepressants~* History of renal insufficiency/renal failure~* Prior allergic reaction to morphine~* Inability to provide informed consent~* Previous entry of patient into study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patient-controlled analgesia 1 mg demand dose (Type: EXPERIMENTAL): 0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes
- Patient-controlled analgesia 1.5 mg demand dose (Type: EXPERIMENTAL): 0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes
- Non-Patient-controlled analgesia comparison group (Type: ACTIVE_COMPARATOR): 0.1 mg/kg morphine loading dose plus additional analgesia as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2 inclusive~Exclusion Criteria:~* females who are pregnant, lactating, or less than 6 weeks post-partum~* current symptomatic heart failure (NYHA Class II-IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- metformin + glimepiride + pioglitazone + albiglutide placebo (Type: ACTIVE_COMPARATOR): Metformin + glimepiride + pioglitazone + matching albiglutide placebo
- metformin + glimepiride + pioglitazone placebo + albiglutide (Type: EXPERIMENTAL): Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
- met + glimepiride + pioglitazone placebo + albiglutide placebo (Type: ACTIVE_COMPARATOR): metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 18.0-35.0 kg/m2~* 45-120 kg, inclusive~* At screening, females must be non-pregnant and non-lactating, or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year postmenopausal (amenorrhoea duration of 12 consecutive months); nonpregnancy will be confirmed for all females by a pregnancy test conducted at screening, (each) admission, and at follow-up.~* Female participants of child-bearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit.~* In good physical health on the basis of no clinically significant findings from medical history, physical examination (PE), laboratory tests, 12 lead ECG, and vital signs, as judged by the Investigator.~* Willingness and able to comply with the study protocol, in the investigator's judgement.~Exclusion Criteria:~* Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.~* Positive drug or alcohol at screening and prior to first dose~* History of alcohol abuse or substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- AL001 (Type: EXPERIMENTAL): Up to six single ascending doses of AL001
- Saline Solution (Type: PLACEBO_COMPARATOR): Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled within two weeks of the screening visit to undergo abdominal or pelvic surgery~* Moderate to severe pain within 6 hours following completion of the required surgery.~Exclusion Criteria:~* Surgical procedure involves a subcostal incision.~* Chronic disease or recent cardiovascular events.~* Known allergy or hypersensitivity to the active compounds or any of the excipients used in the study.~Additional Inclusion/Exclusion Criteria May Apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): intravenous diclofenac dosage level 1
- B (Type: EXPERIMENTAL): intravenous diclofenac dosage level 2
- C (Type: ACTIVE_COMPARATOR): intravenous ketorolac
- D (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Study Parts A and B:~-Cirrhosis of alcohol aetiology according to physician's assessment prior to screening.~Part A:~-Cirrhosis with clinical and/or endoscopic evidence of portal hypertension (e.g. oesophageal varices).~Part B:~* Cirrhosis with TIPSS in situ and PPG\>5mmHg.~* Fully functioning TIPSS without variceal filling as confirmed by portography.~Exclusion Criteria:~Study Parts A and B:~* Use of any drug to treat portal hypertension (e.g. vasodilators such as non-selective beta blockers or nitrates) within 1 month prior to screening.~* Decompensated cirrhosis (Child-Pugh score \>9 points, and/or ascites requiring diuretics, and/or hepatic encephalopathy) at visit 1.~* Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk.~Part A:~* BMI (weight\[kg\] / height\[m\^2\]) \> 40 kg/m\^2.~* Any contraindication to having an MRI scan~Part B:~-Contraindication to catheterization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Terlipressin acetate (Type: EXPERIMENTAL): Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
- Part A: Serelaxin (RLX030) (Type: EXPERIMENTAL): Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
- Part B Serelaxin (RLX030) (Type: EXPERIMENTAL): The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete